Navigation Links
David M. Kendall, M.D., Named Distinguished Medical Fellow at Lilly

INDIANAPOLIS, May 18, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that David M. Kendall, M.D., currently chief scientific and medical officer of the American Diabetes Association, has been named distinguished medical fellow for Lilly. He will transition from his current role in late-July.

In his new role, Kendall will serve as a senior medical advisor for Lilly Diabetes in advocacy and clinical science communities and as a representative to the professional medical community. In addition, he will help provide scientific direction for Lilly in diabetes discovery and clinical development. Other key responsibilities will include the support of Lilly's medical education efforts and diabetes healthcare evaluation programs.

"David brings a critical external view, including the insights he gained while at the American Diabetes Association," said Enrique Conterno, president of Lilly Diabetes. "We are working hard to gain leadership in diabetes care, and that leadership must start with an understanding of the needs of patients and health care providers."

Kendall will report to Robert Heine, M.D., vice president medical affairs, Lilly Diabetes.

"With his background as a clinician, researcher and diabetes advocate, David is the ideal candidate for this position," said Heine. "His focus, passion and understanding of diabetes care will enable us to create ever better solutions for people living with diabetes."

About David Kendall

Kendall joins Lilly Diabetes from the American Diabetes Association, where he serves as scientific and medical officer and has been responsible for the oversight of the Association's research programs, medical affairs, medical education, international affairs, medical information and community programs since 2009.

Kendall also is an associate professor of medicine at the University of Minnesota and an adjunct medical director at the International Diabetes Center, both located in Minneapolis, Minnesota.

Prior to these appointments, Kendall held a number of leadership positions at the International Diabetes Center, and served as faculty at the University of Minnesota Medical School.

Kendall's experience in diabetes spans nearly 25 years, with a research focus on the clinical management of type 1 and type 2 diabetes, emerging novel therapies as well as the treatment and prevention of diabetes complications. He is the author of more than 150 original manuscripts, chapters and professional reviews and a former NIH clinical investigator for both the National Institutes of Diabetes, Digestive and Kidney Diseases and the National Heart, Lung and Blood Institute.

Kendall received his bachelor's degree from St. Olaf College in Northfield, Minnesota, and earned his M.D. and completed his post doctoral training in Diabetes, Endocrinology and Metabolism at the University of Minnesota Medical School in Minneapolis.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy - practical tools, education, and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journeys of each person living with or treating diabetes inspire ours. For more information, visit

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at



SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
2. Dr. David B. Samadi Discusses Why Robotic Surgery is Quickly Becoming the Go-To Standard for Prostate Cancer Treatment
3. Law Offices of John David Hart: DePuy Recalled Hip Device Lawsuit Filed by Houston Woman
4. St. Davids HealthCare Takes Robotic-Assisted Surgery to the Next Level With the Texas Institute for Robotic Surgery at St. Davids North Austin Medical Center
5. International Prostate Cancer Treatment Expert Dr. David B. Samadi Supports Kenyan Minister of Medical Services, Peter Anyang Nyongos Decision to Travel to the U.S. for Prostate Cancer Treatment
6. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
7. Adeona Mourns the Passing of David A. Newsome, M.D., Senior Vice President of Research & Development
8. Codexis Names David Anton CTO & SVP, Process Development & Manufacturing
9. Cayenne Medical, Inc. Appoints David B. Springer President & CEO
10. Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
11. Robotic Surgery Expert Dr. David Samadi, MD Determines Live Robotic Prostate Cancer Surgeries During Israel Trip A Success
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Italian therapeutic drug monitoring ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law firm of ... obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer ... 2015 IL App (2d) 130884WC. , According to court documents, Adcock testified that on ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... ... November 25, 2015 , ... Castlewood Treatment Center ... with eating disorders as a result of the $20,000 raised at the center’s ... Fox Run Golf Club in Eureka, will help individuals who otherwise might not ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):